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In recent years several studies investigated the role of T lymphocyte subpopulations in the pathogenesis of rheumatoid arthritis
(RA). Pathogenic Th17 cells mediate pannus growth, osteoclastogenesis, and synovial neoangiogenesis; hence they are key players
in the development of the disease. On the other hand, regulatory T (Treg) cells are a T cell subset whose peculiar function is
to suppress autoreactive lymphocytes. The imbalance between Th17 and Treg cells has been identified as a crucial event in the
pathogenesis of RA. In addition, the effects of currently employed RA therapeutic strategies on these lymphocyte subpopulations
have been extensively investigated.This review article aims to discuss current knowledge on Treg andTh17 cells in RA and possible
implications of their therapeutic targeting in this disorder.
1. Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory condi-
tion characterized by progressive articular cartilage destruc-
tion and bone resorption [1]. Although articular involvement
dominates the clinical picture in RA, a subgroup of patients
may experience extra-articular manifestations such as pul-
monary disease that significantly worsen disease prognosis
[2, 3].
The breaking of self-tolerance is a hallmark of the
disease leading to the production of autoantibodies such
as rheumatoid factor and anticyclic citrullinated peptide
antibodies. Besides the crucial and well-characterized role of
B lymphocytes in RA pathogenesis, also T cells are active
players in this scenario. In normal conditions, Th1 and
Th2 cells mediate immune responses against intracellular
and extracellular pathogens, respectively. However, both cell
subsets may participate in the development of autoimmunity,
and Th2 cells are also involved in allergy and asthma. In
the last decades, the Th1/Th2 immune response paradigm
was challenged following the identification of additional T
cell subsets with either effector or regulatory activity [4]. In
addition, the observation of Th cell flexibility and plasticity
further contributed to increase of the interest on this issue [5].
Among recently identifiedT cell subsets, includingTh9,Th22,
and follicular Th cells, Th17 and regulatory T (Treg) cells
gained growing scientific interest and have been extensively
investigated in several autoimmune/inflammatory disorders.
Th17 cells are normally responsible for immune responses
against extracellular bacteria and fungi but are also leading
actors in the autoimmunity scenario, while Treg cells mediate
immune tolerance and attempt to maintain lymphocyte
homeostasis.
Their opposite behavior as well as their reciprocal plastic-
ity pointed out the importance ofTh17/Treg cell imbalance in
the pathogenesis of RA. Indeed, a large amount of data has
been published to date, with particular interest on the possi-
ble therapeutic targeting of these cells and their products in
an attempt to overcome the limitation of currently employed
biological therapies.
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Table 1: Studies assessing regulatory T (Treg) cell number and function in the peripheral blood, synovial fluid, and synovial tissue of patients
with rheumatoid arthritis.
Authors (year) Reference Treg cells FoxP3 assessment Treg suppressive activity
PB SF SM PB SF
Cao et al. (2003) [10] = to HD ↑versus RA PB N.A. No N.A. Present
Cao et al. (2004) [11] ↓ versus HD ↑versus RA PB N.A. No N.A. Present
Ehrenstein et al. (2004) [35] N.A. N.A. N.A. Yes Impaired N.A.
van Amelsfort et al. (2004) [12] ↑ versus HD ↑ versus RA PB N.A. No Present ↑ versus RA PB
Mo¨tto¨nen et al. (2005) [13] = to HD ↑ versus RA PB N.A. Yes N.A. Present
Liu et al. (2005) [14] = to HD ↑ versus RA PB N.A. No Present Present
Cao et al. (2006) [15] N.A. ↑ versus RA PB N.A. Yes N.A. Present
Dombrecht et al. (2006) [27] = to HD N.A. N.A. No N.A. N.A.
van Amelsfort et al. (2007) [28] N.A. N.A. N.A. No Present Present
Behrens et al. (2007) [32] N.A. N.A. Present Yes N.A. N.A.
Lin et al. (2007) [25] = to HD N.A. N.A. Yes N.A. N.A.
Jiao et al. (2007) [16] ↓ versus HD ↑ versus RA PB N.A. Yes N.A. N.A.
Han et al. (2008) [24] ↑ versus HD N.A. N.A. Yes Present N.A.
Raghavan et al. (2009) [33] N.A. N.A. Present Yes N.A. Present
Sempere-Ortells et al.
(2009) [19] ↓ versus HD N.A. N.A. Yes N.A. N.A.
Dejaco et al. (2010) [18] = to HD ↑ versus RA PB N.A. No N.A. N.A.
Kawashiri et al. (2011) [20] ↓ versus HD N.A. N.A. No N.A. N.A.
Lina et al. (2011) [23] ↓ versus HD N.A. N.A. Yes N.A. N.A.
Niu et al. (2012) [21] ↓ versus HD N.A. N.A. Yes N.A. N.A.
Xq et al. (2012) [34] N.A. N.A. Present ↑ versus OA-SM N.A. N.A.
Samson et al. (2012) [22] ↓ versus HD N.A. N.A. Yes Present N.A.
Ji et al. (2013) [26] = to HD N.A. N.A. Yes N.A. N.A.
Moradi et al. (2014) [17] = to OA ↑ versus RA PB Present Yes N.A. N.A.
Guggino et al. (2015) [36] ↓ versus HD N.A. N.A. Yes N.A. N.A.
PB: peripheral blood; SF: synovial fluid; SM: synovial membrane; RA: rheumatoid arthritis; OA: osteoarthritis; HD: healthy donors; N.A.: not applicable.
The aim of this paper is the critical discussion of current
knowledge on Treg and Th17 cells in RA and possible
implications of their therapeutic targeting in this disorder.
2. Treg Cells in RA Peripheral
Blood and Synovium
Since their first identification in mice and humans [6], Treg
cells have been extensively investigated in several autoim-
mune disorders including RA. Treg cells can be divided in
two subgroups: natural Treg cells, generated in the thymus
in the early phases of life, and inducible Treg cells that
originate in the periphery throughout the entire life. The
peculiar function of Treg cells is that of preventing autoim-
munity via the suppression of autoreactive lymphocytes.
Such effect is mediated either via cell-cell contact or via
secretion of soluble molecules including interleukin- (IL-) 10
and transforming growth factor- (TGF-) 𝛽. As far as Treg
phenotype is concerned, although Treg cells were initially
identified as CD4+CD25high T cells, recent data suggest that
the expression of CD25 on the cell surface is notmandatory to
confer regulatory properties. In fact, the transcription factor
FoxP3 is currently the most specific Treg cell marker and is
able to ensure suppressive activity independently on CD25
coexpression [7–9].
In the last decade, a consistent number of studies inves-
tigated the number, phenotype, and function of Treg cells in
the peripheral blood, synovial fluid, and synovial membrane
of RA patients (Table 1). It is important to note that,
besides a general agreement on Treg cell enrichment in RA
synovial fluid [10–18], conflicting results have been reported
concerning Treg cell proportion in RA peripheral blood. In
particular, most studies observed reduced circulating Treg
cell percentages in RA compared to healthy individuals [11, 16,
19–23], while some other studies reported either an increase
[12, 24] or similar cell percentages compared to normal
controls [10, 13, 14, 18, 25–27] or patients with osteoarthri-
tis (OA) [17]. These apparently paradoxical discrepancies
deserve some consideration. In earlier studies, Treg cells were
defined as CD4+CD25high cells and FoxP3 coexpression was
not routinely assessed [10–14, 27, 28]. However, in 2008 Han
and coworkers pointed out that CD25high cells include a high
proportion of FoxP3− cells that cannot be classified as Treg
cells [24]. In fact, CD25 can be expressed also by recently
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activated cells that do not coexpress FoxP3 [29]. Hence,
the higher cell percentages of Treg cells reported by some
studies may reflect a contamination of activated cells with
consequent reduced number of the overall FoxP3 expression
among RA peripheral blood CD25high cells compared to
healthy individuals [24]. In addition, other surface markers
that allow the distinguishing of different subsets of natural
and induced Treg cells, such as Neuropilin-1 [30] or Helios
[31], have not been investigated in RA.
Concerning synovial fluid, FoxP3 mRNA expression in
CD25high T cells is higher in both RA and OA compared to
CD25− effector cells [13, 15, 17], as well as in total RA synovial
fluid mononuclear cells compared to total peripheral blood
mononuclear cells [16]. However, flow cytometry data on
FoxP3+ cell percentage among CD25high synovial fluid cells
are not available.
Taken together, these observations allowed the conclu-
sion that although some RA patients display an expansion
of CD25high cells in peripheral blood or synovial fluid, the
identification of real Treg cells, namely, those FoxP3+, should
be recommended to provide more precise cell percentages
and allow a comparison between different studies.
Finally, studies performing synovial immunohistochem-
ical staining to detect FoxP3 consistently reported that Treg
cells are diffusely present in the hyperplastic synovial lining
and in the sublining tissue and that their number increases
in parallel with the worsening of inflammation [32–34].
Furthermore, the only study that quantified CD25high Treg
cells by flow cytometry in cell suspensions obtained from
RA synovial biopsies showed that Treg cell percentage is
significantly higher in this compartment compared to periph-
eral blood and significantly lower compared to synovial fluid
[17].
The evidence of increased percentages of Treg cells both
in RA synovial fluid andmembrane, proven by FoxP3 expres-
sion, may suggest a certain attempt to counteract effector T
cell response in the target organs of the disease. However,
although some in vitro studies reported that suppressive
activity appears to be, at least partially, preserved in Treg cells
from peripheral blood [12, 14, 22, 24, 28] and synovial fluid
[10–15, 28, 33], it should be borne in mind that this may be
an artifact due to the removal of Treg cells from a proinflam-
matory microenvironment. Therefore, any speculation about
the function of Treg cells in vivo in RA should be performed
with caution.
Studies attempting to identify correlations between Treg
cells and clinical/serological features of the disease yielded
often contradictory results [11, 12, 19–21, 24, 26, 32]. An
inverse relationship between disease activity score on 28
joints (DAS28) and the percentage of circulating CD25high
Treg cells has been reported [19–21]. On the other hand,
however, a surprisingly higher percentage of FoxP3+ cells
were also observed amongCD25high Treg cells from active RA
patients [19, 26].
Concerning synovial tissue Treg cells, Behrens et al.
described a direct relationship between synovial T-bet/FoxP3
mRNA ratio and DAS28, suggesting a quantitative Treg
deficiency in RA target tissue [32].
As far as acute phase reactants are concerned, such as
erythrocyte sedimentation rate (ESR) and C-reactive protein
(CRP), either an inverse relationship or no association with
Treg cell proportion has been reported [11, 12, 20, 24]. Finally,
no association between Treg cell percentage and age, sex,
disease duration, rheumatoid factor positivity, and bone
erosions has been identified [11, 12, 20, 24].
In conclusion, although often contradictory, the available
majority of data points out a reduction of circulating, but
an increase of synovial, Treg cells, the latter resulting in a
compensatory mechanism to counteract local inflammation.
3. Proinflammatory Th17 Cells in RA
Peripheral Blood and Synovium
Th17 cells represent a distinct effector T cell subset charac-
terized by the expression of the retinoic acid-related orphan
receptor- (ROR-) 𝛾t and the production of IL-17 family
members, IL-21, and IL-22 [62]. The IL-17 family consists of
six members, from IL-17A to IL-17F. To date, IL-17 refers to
IL-17A, which is the founding member of the IL-17 family.
The polarization of a na¨ıve T cell towards a Th17 cell
is a multistep process requiring a peculiar cytokine milieu
that includes IL-6, TGF-𝛽, IL-21, IL-1𝛽, and IL-23 [5, 63].
Of interest, however, a recent paper provided evidence that
pathogenic Th17 cells could be generated also in the absence
of TGF-𝛽 signaling [64].
IL-17 is involved in several physiological and patholog-
ical processes as the binding to its receptor leads to the
release of proinflammatory mediators, including cytokines,
chemokines, and matrix metalloproteinases (MMPs), by the
target cell. Therefore, the pathogenic role of IL-17 and IL-17-
producing cells has been extensively investigated in a variety
of inflammatory and autoimmune diseases [65].
Regarding RA pathogenesis, data from experimental
models support the role of IL-17 in pannus growth, RANKL-
independent osteoclastogenesis [66–68], and synovial neoan-
giogenesis [55, 69]. In humans, in vitro studies revealed that
recombinant IL-17 is able to potentiate the expression of
proinflammatory cytokines and prostaglandin E2 in synovial
tissue cells, confirming its role in inducing pannus growth
and osteoclastogenesis in vivo [38, 44, 67]. Furthermore, its
proangiogenic potential is also confirmed by the evidence
that recombinant IL-17 enhances the production of vascular
endothelial growth factor-A in RA synovial fibroblasts [47].
Similarly, when cocultures were arranged with peripheral
blood mononuclear cells and synovial Th17 cells instead
of recombinant IL-17, a strong enhancement of IL-6, IL-8,
MMP-1, and MMP-3 production by RA synovial fibroblasts
was observed [54].
At present, several studies evaluating IL-17 and IL-17-
producing cells in human RA are available (Table 2) [70].
Concerning IL-17 in biologic fluids, it has been largely
investigated since early 2000s. Most studies observed higher
concentration of this cytokine in the serum [40, 42, 44,
49, 50, 71] and in the synovial fluid [38–40, 44, 51] of RA
patients compared to normal subjects or OA patients. In
striking contrast, two studies observed comparable serum
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Table 2: Studies assessingTh17 cells and IL-17 in the peripheral blood, synovial fluid, and synovial tissue of patients with rheumatoid arthritis.
Authors (year) Reference Th17 cells IL-17 concentration
PB SF SM Serum SF
Chabaud et al. (1999) [37] N.A. N.A. ↑ versus OA N.A. N.A.
Kotake et al. (1999) [38] N.A. N.A. ↑ versus OA N.A. ↑ versus OA
Ziolkowska et al. (2000) [39] N.A. N.A. N.A. N.A. ↑ versus OA
Kageyama et al. (2007) [40] N.A. N.A. N.A. ↑ versus HD ↑ versus OA
Yamada et al. (2008) [41] = versus HD ↓ versus RA PB N.A. N.A. N.A.
Shen et al. (2009) [42] ↑ versus HD N.A. N.A. = versus HD N.A.
Shahrara et al. (2008) [43] N.A. ↑ versus RA PB ↑ versus OA N.A. N.A.
Moran et al. (2009) [44] N.A. N.A. ↑ versus OA ↑ versus OA ↑ versus OA
Shen et al. (2010) [45] ↑ versus HD N.A. N.A. ↑ versus HD N.A.
Aerts et al. (2010) [46] = versus HD N.A. N.A. N.A. N.A.
Gullick et al. (2010) [47] ↑ versus HD ↑ versus RA PB Present N.A. N.A.
Hueber et al. (2010) [48] N.A. N.A. ↑ versus OA N.A. N.A.
Chen et al. (2011) [49] ↑ versus HD N.A. N.A. ↑ versus HD N.A.
Lina et al. (2011) [23] ↑ versus HD N.A. N.A. N.A. N.A.
Metawi et al. (2011) [50] N.A. N.A. N.A. ↑ versus HD ↑ versus OA
Suurmond et al. (2011) [51] N.A. N.A. = versus OA N.A. ↑ versus OA
Samson et al. (2012) [22] ↑ versus HD N.A. N.A. N.A. N.A.
Arroyo-Villa et al. (2012) [52] ↓ versus HD N.A. N.A. ↓ versus HD N.A.
Zhang et al. (2012) [53] ↑ versus HD N.A. N.A. N.A. N.A.
van Hamburg et al. (2013) [54] ↑ versus HD = versus RA PB N.A. N.A. N.A.
Niu et al. (2012) [21] ↑ versus HD N.A. N.A. N.A. N.A.
Kim et al. (2013) [55] ↑ versus HD and OA N.A. N.A. ↑ versus HD N.A.
Li et al. (2013) [56] N.A. N.A. Present N.A. N.A.
Henriques et al. (2013) [57] ↑ versus HD N.A. N.A. N.A. N.A.
van Baarsen et al. (2014) [58] N.A. N.A. Present N.A. N.A.
Fazaa et al. (2014) [59] = versus HD N.A. N.A. = versus HD N.A.
Sarkar and Fox (2010) [60] ↑ versus OA Absent N.A. N.A. N.A.
Miao et al. (2014) [61] ↑ versus HD N.A. N.A. N.A. N.A.
Guggino et al. (2015) [36] ↑ versus HD N.A. N.A. N.A. N.A.
PB: peripheral blood; SF: synovial fluid; SM: synovial membrane; RA: rheumatoid arthritis; OA: osteoarthritis; HD: healthy donors; N.A.: not applicable.
levels of this cytokine in RA and controls [42, 59] and
another reported reduced concentration of serum IL-17 in RA
compared to controls [52].
Such discrepancies in the serum levels of IL-17 may be
clarified, at least in part, in those studies in which also circu-
lating Th17 cells were enumerated. When available, indeed,
the concentration of serum IL-17 appeared to parallel the
number of circulatingTh17 cells. In particular, in three studies
in which IL-17 was detected at higher concentrations in long-
standing RA compared to healthy subjects, the percentage of
circulatingTh17 cells was also significantly higher [42, 49, 71].
Arroyo-Villa et al. reported reduced levels of both IL-17 and
Th17 cells in early RA patients [52], while Fazaa et al. failed to
observe any differences in the Th17 cell percentage and IL-17
concentration between patients and controls [59]. Although
Shen et al. did not observe any differences in serum IL-17
concentrations, they found higher Th17 cell percentages in
RA patients [42].
Additional studies investigated circulating or synovial
fluid Th17 cells without the concurrent evaluation of IL-17.
In the majority of these, higher percentages of circulating
Th17 cells were detected in RA compared to healthy or OA
controls [21–23, 36, 47, 53, 54, 57, 60, 61], while in few
others Th17 cell proportion in RA was comparable to that
of healthy subjects [26, 41, 46]. In synovial fluid, the pro-
portion of Th17 cells was either higher [43, 47], comparable
[54], or reduced [41] compared to that found in peripheral
blood.
A further complication to this issue comes from the fact
that some studies were performed in patients with established
RA and others in early RA. In established RA, there is general
agreement that circulating Th17 cells are increased in the
peripheral blood compared to healthy subjects, even if some
authors reported Th17 cell proportions overlapping that of
healthy donors [26, 40, 59]. Conversely, in the available stud-
ies in early RA, either higher [36, 54] or lower percentages
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[52] of circulating Th17 cells with respect to healthy subjects
were described.
Studies evaluating IL-17 in synovial tissue reported
increased immunostaining as well as mRNA expression in
RA synovial membrane compared to OA [37, 38, 43, 44, 47,
48, 51, 56, 58]. Although in RA synovium IL-17+ cells are
mostly CD4+ cells [38] mainly localized in the T cell area
[37]; also macrophages and mast cells appear to be a local
source of IL-17 [48, 51, 58].Moreover, a recent study identified
IL-17+FoxP3+ T cells in human RA synovial tissue [72]. This
observation is in line with data obtained in experimental
arthritis reporting that Th17 cells can arise from Treg cells
following FoxP3 loss. These so-called exFoxP3 Th17 cells
appear to be more pathogenic than those originating from
na¨ıve T cells [72].
Finally, several studies also investigated possible corre-
lations between IL-17 or Th17 cell proportion and disease
activity. Most studies agree that serum IL-17 concentration
[50, 71, 73] and circulating Th17 cell percentage [21, 53, 61]
positively correlate with DAS28. In addition, synovial IL-
17 staining was found to be directly correlated with DAS28
[47, 56]. To note, a direct correlation between synovial fluid
Th17 cell percentage and ultrasound power Doppler signal in
the corresponding joint has been also reported [47]. Finally,
synovial fluid IL-17 was correlated with the degree of intimal
lining layer hyperplasia in paired synovial samples [73].
Concerning serological features of the disease, serum IL-17
levels appear to be directly correlated with both CRP and ESR
[45, 71], and synovial fluidTh17 cell proportion appears to be
directly correlated with CRP [47].
In conclusion, Th17 cells and their products appear to be
leading players in RA pathogenesis, and an overall increase of
both has been widely demonstrated. These findings, together
with the aforementioned impairment of Treg cells, depict an
intriguing pathogenic scenario worth targeting for therapeu-
tic purposes.
4. The Effects of Different RA Therapeutic
Approaches on Treg and Th17 Cells
The growing number of studies supporting Treg/Th17 cell
imbalance as pathogenic mechanism in RA prompted to
investigate the effect of currently employed therapies on these
cell subsets (Figure 1).
4.1. Corticosteroids and Disease Modifying Antirheumatic
Drugs. Corticosteroids (CS) are well known modulators of
Treg cells as widely documented in asthma [74]; however
very few data on this issue are available in RA. Recently,
de Paz et al. published two interesting studies that linked
higher percentages of circulating CD4+CD25high Treg cells
and CD25−FoxP3+ T cells to CS treatment in RA [75, 76].
The latter were already identified by Raghavan et al. in RA
synovial fluid [33]. CD25−FoxP3+ T cell expansion has been
also found in systemic lupus erythematosus (SLE) [77], but
its suppressive activity is a matter of debate [78]. We recently
demonstrated that, among CD25− T cells, those coexpressing
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Figure 1:Therapeutic targeting of Treg andTh17 cells in rheumatoid
arthritis (RA). The figure displays currently employed therapeutic
approaches in RA for which an effect on Treg and Th17 cells
has been reported in the literature (see text for details). Other
compounds depicted in the figure are currently under investigation
in RA or have been tested in experimental models of the disease.
CTLA-4: cytotoxic T lymphocyte antigen 4; IL: interleukin; TGF-𝛽:
transforming growth factor-𝛽; TNF: tumor necrosis factor.
glucocorticoid-induced tumor necrosis factor receptor-
related protein (GITR) display consistent suppressive activity
and are expanded in SLE and primary Sjo¨gren syndrome
(pSS) [79–81]. Intriguingly, since GITR is a CS-inducible
molecule, it would be of great interest to clarify whether the
increase of CD25−FoxP3+ cells that de Paz et al. observed in
CS-treated RA patients [75, 76] was due to a selective increase
of CD25−FoxP3+GITR+ rather than CD25−FoxP3+GITR− T
lymphocytes.
In striking contrast, a reduction of FoxP3 staining in
synovial samples obtained from RA patients before and after
intra-articular CS treatment, in parallel with the general
reduction in inflammation, has been also described [33]. In
light of the observation byKomatsu et al. concerning the pres-
ence of FoxP3+IL-17+ cells inRA synovium [72], an intriguing
explanation for the synovial FoxP3+ cell reduction induced by
CS may be a selective depletion of exFoxP3+Th17 cells.
Th17 cells appear to be major players in the context
of CS resistance in inflammatory diseases. In particular,
a recent study revealed that pathogenic proinflammatory
Th17 cells could be identified by their distinct phenotype
(CCR6+CXCR3hiCCR4loCCR10−CD161+) that includes the
stable expression of P-glycoprotein/multi-drug resistance
type 1. To note, when these cells were isolated from healthy
subjects and cultured with CS, they resulted in being refrac-
tory to these compounds [82]. In this setting, we reported
that IL-17-producing CD3+CD4−CD8− double negative T
cells isolated from pSS patients, but not those from healthy
subjects, are insensitive to dexamethasone in vitro [83]. On
this basis, the selective depletion of CS-resistantTh17 cells, on
one hand, and the understanding of molecular mechanisms
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responsible for CS resistance of double negative T cells, in an
attempt to revert it, on the other hand, are intriguing issues.
In the matter of disease modifying antirheumatic drugs
(DMARDs), there are no studies reporting in vivo Treg or
Th17 cell modulation exerted by these compounds in RA
patients.
A recent study evaluated ovalbumin-immunized mice
treatedwithmethotrexate (MTX), cyclophosphamide (CTX),
or a combination of the two drugs. It was observed
that MTX+CTX, but not each compound in monotherapy,
induced Treg skewing and Th17 suppression by interference
with dendritic cell maturation and antigen presenting ability
[84].
To date, a few studies reportedMTX in vitro effects in RA
[36, 85–87]. The exposure of peripheral blood mononuclear
cells isolated from RA patients to this compound led to a
consistent upregulation of FoxP3, TGF-𝛽, and IL-10 in CD4+
cells, an enhancement of Treg cell suppressive activity [85],
and a reduction of IL-17 mRNA [86]. In addition, our group
has demonstrated that MTX is able to downregulate IL-17
and related cytokines, namely, IL-6, IL-22, and IL-23, but
not IL-21, in culture supernatants of RA peripheral blood
mononuclear cells [85]. Finally, a reduction of Th17 cell
percentage following MTX in vitro exposure has been also
described in patients with early, but not long-standing, RA
[36]. Of interest, the MTX-induced upregulation of FoxP3 in
peripheral bloodmononuclear cells isolated fromRApatients
was not seen in mononuclear cells from healthy subjects
[85, 87].
About hydroxychloroquine, the only study available to
date reported that the addition of this compound to RA
peripheral blood mononuclear cells in vitro is able to reduce
IL-17, IL-6, and IL-22 secretion in culture supernatants
[88].
4.2. Antitumor Necrosis Factor Agents. In the last decade, a
growing number of studies underscored the effects of biologic
agents on Treg and Th17 cells in RA. Concerning Treg cells,
the possible role of tumor necrosis factor (TNF) blockers on
this cell subset was initially reported by Ehrenstein et al. in
2004 [35]. In fact, they observed that treatment with inflix-
imab, a chimeric monoclonal antibody against TNF, was able
to increase the percentage of circulating CD4+FoxP3+ cells
and to revert the defective suppressive activity of CD25high
Treg cells [35]. To note, however, the increase of circulating
CD4+FoxP3+ cells induced by infliximab was due to a selec-
tive upregulation of the FoxP3 transcription factor in CD25−
rather than CD25high T cells [89]. Hence, in a coculture sys-
tem of RA CD25− and CD25high T cells, the apparent restora-
tion of CD25high Treg cell suppressive activity following
infliximab treatmentwas an artifact due to increased percent-
age of suppressive FoxP3+ cells among the CD25− fraction.
Subsequently, several studies attempted to investigate the
effect of other commercially available TNF blockers on RA
Treg cells. Concerning the humanmonoclonal antibody adal-
imumab, while two studies failed to observe any differences in
Treg cell percentage before and after treatment [27, 90], three
other groups reported increased percentages of circulating
CD25high FoxP3+ Treg cells either in accordance with [91] or
independently from clinical response to adalimumab [92, 93].
Moreover, Treg cells isolated from RA patients with good
clinical response to adalimumab appear to exert a more
pronounced suppressive activity [91, 93]. Increased FoxP3
expression among CD4+ lymphocytes has been described in
patients treated with etanercept, a fusion protein acting as
TNF inhibitor [94], but these data were not confirmed in
other studies evaluating the in vivo effects of this compound
on RA Treg cells [90, 91].
The exact molecular mechanism underlying the possible
inhibitory effect exerted byTNFonTreg cells, thus explaining
theirmodulation byTNFblockers, was only recently clarified.
Valencia et al., indeed, observed that TNF is directly respon-
sible for the impaired suppressive activity of RA CD25high
Treg cells, as it determines a consistent reduction of FoxP3
mRNA, required to convey a regulatory activity [95]. This
effect appeared to be mediated through TNFRII that is
constitutively expressed by Treg cells [95]. More recently,
Nie et al. demonstrated that FoxP3 transcriptional activity
and Treg cell suppressive function are regulated by TNF-
dependent dephosphorylation of the FoxP3 DNA-binding
domain (Ser418 in the C-terminal DNA-binding domain)
[96, 97]. This abnormal dephosphorylation of FoxP3 in
RA Treg cells is due to the ubiquitous enzyme protein
phosphatase 1 that is induced by TNF through the IKK–
NF-𝜅B pathway. Of interest, treatment of RA patients with
TNF blockers decreased protein phosphatase 1 expression,
increased FoxP3 phosphorylation, and, in consequence,
restored Treg cell suppressive activity.
As far as the IL-17 axis is concerned, there is general agree-
ment that infliximab or adalimumab-treated RA patients
display lower percentages of circulating Th17 cells [45, 91,
92, 98]. In striking contrast, increase of circulatingTh17 cells
in adalimumab-treated versus anti-TNF-na¨ıve RA patients,
independently of clinical response, has been observed [46].
However, Th17 cells of adalimumab-treated patients with
inactive disease displayed very low levels of the chemokine
receptor CCR6, allowing postulating that although increased,
Th17 cells are not able to migrate to RA target tissue in
these patients [46]. Etanercept, instead, appears to affect
neither the percentage of circulating Th17 cells [91] nor the
concentration of serum IL-17 but is able to decrease serum
IL-23 concentration [40].
In light of these findings, Treg cell specific targeting
may be an additional rationale to employ TNF blockers in
RA. As far as Th17 cells, although conclusive data are still
lacking, the possible biases due to concurrent treatments that
affect T cells, mainly CS, should be taken into account, and
it is conceivable that prospective studies may help to shed
additional light on this issue.
4.3. Abatacept. The first description of cytotoxic T lym-
phocyte antigen 4 (CTLA-4) abnormalities in functionally
defective Treg cells in RA dates back to 2008, when reduced
levels and increased internalization rate of CTLA-4 were
described in Treg cells from RA patients compared to those
from healthy subjects [99]. Since the artificial induction of
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CTLA-4 expression on RA Treg cells restored their suppres-
sive capacity and CTLA-4 blockade on healthy Treg cells
hampered their function, the authors speculated that CTLA-4
on RA Treg cells may represent a potential therapeutic target
to directly interfere with these cells.
The mechanism underlying the impairment of CTLA-4
system in RA was unmasked in a recent study showing that
downregulation of CTLA-4 expression in RA Treg cells is
caused by methylation of a newly identified NF-AT binding
site within the CTLA-4 gene promoter [100]. Of particular
interest, this finding may also help to understand, at least in
part, why RA Treg cells are functionally defective. In fact,
the binding of CD80/CD86 on dendritic cells by CTLA-4
expressed on normal Treg cells induces the activation of
the indoleamine 2,3-dioxygenase (IDO) enzyme [101, 102].
In RA, the reduced CTLA-4 gene transcriptional activity,
due to the aforementioned epigenetic modification, prevents
the activation of the IDO immune-modulatory pathway in
antigen presenting cells (APCs) and, therefore, contributes to
defective Treg cell function [101, 102].
On this basis, the effects on RA Treg cells of abatacept,
a CTLA-4 immunoglobulin currently employed to treat
this disorder, have been subsequently investigated. CTLA-
4 immunoglobulin exerts its immune-modulatory effect via
agonism of CD80/CD86 expressed by APCs by blocking the
second signal required for the activation of effector T lym-
phocytes as well as licensing APCs to express IDO [103, 104].
Either a reduction [105, 106], no modification [107], or
an increase [108] of circulating CD25high and FoxP3+ Treg
cells in abatacept-treated RA patients has been reported.
Furthermore, abatacept treatment in RA appears to restore, at
least in part, the defective suppressive activity of circulating
Treg cells [105, 107], but this observation was not confirmed
by in vitro experiments with synovial fluid Treg cells [106].
To date, only two studies assessed the possible effect
of abatacept on circulating Th17 cells, but they obtained
opposite results. In fact, Scarsi et al. reported a reduction
of the proportion of Th17 cells [108], while Pieper et al. did
not observe any modification in this cell subset following
abatacept therapy [106].
The involvement of CTLA-4 in Treg cell biology is an
intriguing issue. However, the targeting of this molecule did
not provide the expected results. In addition, it is unclear how
CTLA-4may participate inTh17 cell balance, and the few data
available do not allow the drawing of definitive conclusions.
4.4. Tocilizumab. Thenotion that IL-6 is the key cytokine that
determines the commitment of a na¨ıve T lymphocyte towards
a Treg or aTh17 cell prompted the investigation of the effects
of its blockade on Treg/Th17 cell balance in autoimmune
diseases, including RA. Evidence from experimental models
of RApointed out that early treatmentwith anti-IL-6 receptor
antibody led to a reduced frequency of circulating Th17 cells
and, therefore, to a milder clinical picture [109]. Of interest, if
treatment was administered later in the course of the disease,
these effectswere no longer detectable [109]. In linewith these
findings, a study investigating the effects of the commercially
available anti-IL-6 receptor antibody tocilizumab in early RA
revealed a similar reduction of circulating Th17 cells after
three months of treatment [110]. Such decrease, however,
was confirmed only in another study enumerating Th17 cell
frequencies after four months of tocilizumab treatment [22].
In fact, other studies did not observe any differences in Th17
cell percentages up to 6 months after treatment [111, 112].
Concerning Treg cells, progressive increase of their
proportion starting from the first month of therapy with
subsequent stability overtime in the 12-month follow-up has
been described in all the available studies [22, 112, 113] except
one that reported a surprising reduction of circulating Treg
cells induced by tocilizumab in early RA [110].
On this basis, it appears that IL-6 blockade rebalances
Treg/Th17 cell ratio in RA affecting at least one of these T
cell subsets, Treg cells. An intriguing perspective may be to
concurrently target IL-6 and other cytokines involved inTh17
cell polarization to clarify whether this approachmay provide
additional clinical benefit.
4.5. IL-17 Targeted Therapies and Other Future Perspectives.
Taking the well-characterized pathogenic role of IL-17 axis in
autoimmune diseases, in recent years a variety of compounds
targeting this system at different levels are being intensively
investigated [114]. Although the direct blockade of IL-17 with
either fully human or humanized monoclonal antibodies,
such as secukinumab and ixekizumab, respectively, may be
the most straightforward approach for RA, results from
clinical trials revealed lower clinical efficacy than expected for
these compounds. This may be explained, at least in part, by
the heterogeneous expression of IL-17 in RA synovial tissue
and may be overcome by patient stratification based on IL-17
expression [58].
Alternatively, the targeting of molecules involved ups-
tream in the process of Th17 cell generation may be con-
sidered. In this setting, ustekinumab, an anti-p40 subunit
of IL-12/IL-23 monoclonal antibody currently employed for
the treatment of plaque psoriasis, is under investigation in
chronic inflammatory arthritides [115, 116]. Guselkumab, a
human IL-23-specific monoclonal antibody recently evalu-
ated in psoriasis [117], may also find a therapeutic application
in RA as well as NNC114-0005, an anti-IL-21 antibody that
was investigated in RA in phase I trials [118].
In addition, a very intriguing therapeutic approach is
represented by the interference with Th17 cell generation
using small molecules able to modulate ROR𝛾t expression.
An elegant study recently showed an improvement of neu-
rological symptoms in an experimental model of multiple
sclerosis treatedwith the high-affinity synthetic ligand SR1001
specific to both ROR𝛼 and ROR𝛾t that inhibits Th17 cell
differentiation and function [119].
In line with the current knowledge on the role of Treg and
Th17 cells in RA pathogenesis, however, the identification of
a therapeutic approach able to rebalance their ratio concur-
rently targeting both cell subsets may be the most suitable
choice. In this setting, the blockade of different cytokine
systems by bispecific antibodies is an intriguing possibility.
In a mouse model of RA, combined TNF/IL-17 inhibi-
tion resulted in virtual abrogation of synovitis similarly to
anti-TNF monotherapy, but with superior effect on bone
erosion compared to anti-TNF or anti-IL-17 monotherapies
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[120]. On the basis of this observation, the same group
recently developed and characterized a bispecific antibody
to target both TNF and IL-17 and tested this compound in
RA fibroblast-like synoviocytes (FLS) in vitro [120]. When
RA-FLS were stimulated with either TNF or IL-17 alone
and treated with the corresponding blocking antibody or
the bispecific one, a similar reduction of proinflammatory
cytokine release was observed in the three conditions. Of
great interest, however, when RA-FLS were stimulated with
both TNF and IL-17, the bispecific antibody exhibited a
greater inhibitory effect on proinflammatory cytokine release
compared to single blocking antibodies [120]. Since RA-FLS
are exposed to a heterogeneous proinflammatory milieu
in vivo, this therapeutic approach seems to represent an
intriguing option worth investigating further.
Finally, possible effects of B-cell targeted therapies on
Treg and Th17 cells deserve some considerations. The initial
observation by Me´let et al. that the anti-CD20 antibody
rituximab induces a consistent depletion of circulating T
cells, mainly those CD4+, in RA patients prompted the
investigation of the specific T cell subset possibly affected
by this compound as well as the mechanism at the basis
of this effect [121]. Although Treg cells do not appear to
be affected by rituximab [122, 123], a recent investigation
reported that rituximab was able to reduce, at least in
rheumatoid synovium, the Th17, but not Th1, response [122].
Of interest, a subset of IL-17-producing cells isolated from
the peripheral blood of healthy subjects coexpresses CD20,
and these CD20+IL-17+ T lymphocytes are expanded in the
circulation of RA patients [124].
These intriguing observations further underscore the
therapeutic rationale for rituximab in RA, as it appears able to
target not only the pathogenic B-cell compartment, but also
the T cell compartment in this disease.
In conclusion, most of the currently employed therapeu-
tic approaches in RA appear able also to target Treg/Th17 cells
and this contributes to their clinical efficacy. It would be of
interest, however, to verify whether the selective targeting of
these cell subsets may provide additional clinical benefit, thus
further supporting the rationale to include these compounds
in clinical practice.
5. Conclusions
In conclusion, a large body of evidence supports the concept
that an imbalance between Treg and Th17 cells is a crucial
aspect in the pathogenesis of RA. Although often contradic-
tory, most studies agree that an overall depletion of Treg and
a parallel increase of Th17 cells in the peripheral blood and
target organs could be detected in RA patients. In addition,
intrinsic cell abnormalities, involving genetic and epigenetic
modifications, may explain the defective suppressive activity
of RA Treg cells.
Currently employed therapeutic strategies, mostly biote-
chnologic agents, appear to actively interfere with Treg and
Th17 cells and restore either their correct proportion or,
for Treg cells, their suppressive function. However, although
intriguing, this evidence needs to be confirmed in larger
prospective studies.
The new therapeutic compounds currently under investi-
gation in RA, such as anti-IL-17 antibodies or anti-TNF/IL-
17 bispecific antibodies, represent a promising option and
studies aimed at characterizing their activity onTreg andTh17
cells will be of great interest.
Finally, the increasing knowledge on Treg cell markers
and selective isolation proceduresmay allow directly employ-
ing ex vivo expanded Treg cells for therapeutic purposes in
RA, eventually aiming at the reset of the immune system and
restoration of tolerance [125, 126].
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